Send us a textA blocked artery isn’t the end of the story—what happens when blood rushes back can decide how much tissue survives. We sit down with Nyrada CEO James Bonner to unpack how Xolatryp, a small molecule TRPC channel blocker, aims to protect mitochondria, cut calcium overload, and reduce injury after heart attack, traumatic brain injury, and stroke. With Phase I safety in the bank and a Phase IIA study planned for PCI patients, we dig into the practical metrics that matter: MRI‑based infarct size, blood biomarkers, heart function, and arrhythmia rates.James explains why mitochondrial stability is the hinge point in ischemia‑reperfusion injury and how preclinical work with the Walter Reed Army Institute of Research supports Xolatryp’s mechanism. We talk through the study design choices that bring the drug into the cath lab at the right moment, the potential to standardize dosing alongside angioplasty, and the broader clinical logic that could translate across cardiology and neurology. The conversation also explores Nyrada’s IP moat with a composition‑of‑matter patent, the company’s lean, virtual operating model, and a funding plan combining new equity and R&D rebates to carry the program through Phase IIA.If you care about where the next leap in acute care may come from, this is a grounded look at a therapy built for minutes‑matter medicine. We share Nyrada’s two‑to‑three‑year outlook, including a licensing‑by‑indication strategy across key markets, and frame the market size anchored by roughly two million annual PCI procedures in developed regions. Subscribe for more ASX‑focused biotech briefings, share this with a colleague who tracks cardiovascular or neuro trauma innovations, and leave a review to tell us which endpoints you believe should define success.

Ver todos los episodios